Submission of newspaper publication w.r.t un-audited financial results for the quarter & nine months ended 31.12.2025
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) submitted copies of its newspaper publication of unaudited standalone financial results for the quarter and nine months ended 31 December 2025, published in Financial Express and Jansatta. For Q3 FY26, the company reported total operating income of Rs. 4.38 lacs and a net loss after tax of Rs. 22.03 lacs (EPS of Rs. -0.12), compared to a net loss of Rs. 17.46 lacs in Q3 FY25. For the nine-month period, the net loss after tax widened to Rs. 66.06 lacs (EPS of Rs. -0.35) versus Rs. 17.25 lacs a year earlier. Equity share capital stood at Rs. 1,911.14 lacs, unchanged.
The widening year-on-year losses signal continued financial pressure on the company, which is a negative indicator for shareholders. The renaming to MPS Pharmaa Limited may hint at a strategic pivot, but operational performance remains weak with negligible revenue and persistent losses.